ADAM17 and metabolic dysfunction-associated steatotic liver disease: Together, these results show that loss of ADAM17 in adipose tissues protects from lipotoxicity-derived non-alcoholic fatty liver disease (NAFLD) development typified by increased hepatic lipid uptake, and decreased oxidation and export [83].